Approval Year
| Substance Class |
Concept
|
| Record UNII |
37XME2A3QC
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
37XME2A3QC
Created by
admin on Wed Apr 02 19:28:30 GMT 2025 , Edited by admin on Wed Apr 02 19:28:30 GMT 2025
|
PRIMARY | |||
|
2419130-28-0
Created by
admin on Wed Apr 02 19:28:30 GMT 2025 , Edited by admin on Wed Apr 02 19:28:30 GMT 2025
|
NO STRUCTURE GIVEN | |||
|
DB15599
Created by
admin on Wed Apr 02 19:28:30 GMT 2025 , Edited by admin on Wed Apr 02 19:28:30 GMT 2025
|
PRIMARY |
This is a non-substance concept
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
OFF TARGET->WEAK INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
>?1300-fold selectivity towards other human cathepsins.
IC50
|
||
|
OFF TARGET->WEAK INHIBITOR |
IC50
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
OFF TARGET->WEAK INHIBITOR |
IC50
|
||
|
OFF TARGET->WEAK INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Phase II: MIV-711 was not more
effective than placebo for pain,
but it significantly reduced bone
and cartilage progression with a
reassuring safety profile.
|
This is a non-substance concept